ABI
CTRX

Adamant Biomedical Investments’s CATAMARAN CORP COM STK (CDA) CTRX Stock Holding History

Adamant Biomedical Investments’s Portfolio CTRX Stock Details CTRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$10.7M Buy
206,820
+70,080
+51% +$3.29M 2.57% 8
2014
Q3 		$5.25M Buy
+136,740
New +$6.22M 1.31% 24

Other funds holding CTRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return
MNA
Manning & Napier Advisors Fairport, New York $7.09B AUM 17.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Adamant Biomedical Investments's CTRX Position: Q4 2014 in Review

Adamant Biomedical Investments increased its CATAMARAN CORP COM STK (CDA) (CTRX) stake by 51% in Q4 2014, buying an estimated $3.29M and bringing the position to 206,820 shares worth $10.7M. The position accounts for 2.57% of the portfolio, ranked #8.

Adamant Biomedical Investments first reported a position in CTRX in Q3 2014 and has held it in 2 quarters since. 339 funds tracked by Wall St. Rank hold CTRX as of Q4 2014.

  • Adamant Biomedical Investments held 206,820 shares of CATAMARAN CORP COM STK (CDA) worth $10.7M as of Q4 2014.
  • Adamant Biomedical Investments bought 70,080 CATAMARAN CORP COM STK (CDA) shares in Q4 2014, an estimated $3.29M.
  • CATAMARAN CORP COM STK (CDA) made up 2.57% of Adamant Biomedical Investments's portfolio in Q4 2014, its #8 holding.
  • Adamant Biomedical Investments first reported a position in CATAMARAN CORP COM STK (CDA) in Q3 2014 and has held it in 2 quarters since.
  • 339 funds tracked by Wall St. Rank held CATAMARAN CORP COM STK (CDA) as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.